200 million levels of Japanese cardiovascular drugs without a copy? The Shijiazhuang pharmaceutical company is hitting again.

Pharmaceutical Network August 24 - August 21, CDE official website data show that Shijiazhuang Gree Pharmaceuticals hydrochloric acid Arolol tablets 4 imitation market applications to be undertaken.
arolol tablet original research enterprises for Japan's Family friends, the current domestic market only import approval.
Figure 1: Shijiazhuang Gree Pharmaceuticals' registration of hydrochloric acid arolol tablets Source: CDE official website Figure 2: Sales of hydrochloric acid arolol tablets Source: Minnet China's public medical institutions terminal competition pattern hydrochloric acid arolol tablets for the 3rd generation beta blocker, used to treat primary hypertension (light-moderate), angina, arrhythmia, primary tremor. according to
data, the product was listed in Japan in 1985, landed in the Chinese market in 1995, is currently a category B variety of the national health insurance catalogue, in 2019 in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal sales of nearly 200 million yuan.
3: Clinical situation of hydrochloric acid arolol tablets Source: Minet China Drug Clinical Trials PublicIty Library original research listed in China for more than 20 years, domestic generic drugs are actually a blank? Milnenet data show that Shijiazhuang Gree Pharmaceuticals in July 2015 declared 6 types of imitation listing, in October 2016 was approved clinical, in July 2019 completed BE, the recent declaration of 4 types of imitation listing was accepted.
only one company has declared its listing, can the "one-market dispute" be adhered to until the first imitation is approved? We'll see.
source: CDE official website, Minet database review data statistics as of August 21, 2020, if there are errors, please point out.
.